Pomc Deficiency Obesity

• EMA approval · 2026-04-07
  EMA Authorised: Imcivree (setmelanotide) — Rhythm Pharmaceuticals Netherlands B.V.

  The European Medicines Agency authorised Imcivree (setmelanotide) for obesity, including rare genetic disorders of the melanocortin-4 recept…

• FDA approval · 2026-03-19
  FDA Approved: IMCIVREE — Supplemental Application (Rhythm Pharmaceuticals, Inc)

  FDA approved a supplemental application for IMCIVREE (setmelanotide) to expand its indications for genetic obesity disorders. The approval b…

• FDA approval · 2025-08-21
  FDA Approved: IMCIVREE — Supplemental Application (Rhythm Pharmaceuticals, Inc)

  The FDA approved a supplemental application for IMCIVREE (setmelanotide) submitted by Rhythm Pharmaceuticals, Inc.